Optiscan Imaging (OIL) Q2 2025 TU earnings summary

Executive summary

• Achieved key milestones in product development, including delivery of the first flexible GI scope prototype and progress on InVue® and ViewnVivo® systems for clinical and research use.

• Entered a Collaborative Research Agreement with the University of Minnesota for veterinary imaging and advanced AI solutions for gastroenterology with Monash University.

• Expanded business development activities in the US, Europe, and China, with increased sales pipeline and delivery of systems to major research institutions.

• Enhanced brand awareness through industry conferences, media engagement, and strategic presentations.

Financial highlights

• Receipts from customers for the quarter were $0.379m, with a year-to-date total of $1.017m, up 72% year-over-year.

• R&D investment totaled $1.312m for the quarter, supporting multiple parallel projects.

• Received $0.398m in government grant funding and secured an Advance Overseas Finding for R&D tax incentives, expected to provide over $0.5m in annual rebates.

• Cash balance at quarter end was $7.28m, with net cash used in operating activities of $(1.691)m for the quarter.

Outlook and guidance

• On track to deliver on strategic R&D and clinical milestones in the second half of FY25, including product launches and expanded clinical trials.

• Focused on advancing surgical, pathology, gastrointestinal, telepathology, and robotics projects toward commercialization.

• Veterinary imaging device development and market entry activities to continue, targeting unveiling in early FY26.